$44.75
6.07% yesterday
Nasdaq, Nov 15, 10:00 pm CET
ISIN
US90400D1081
Symbol
RARE
Sector
Industry

Ultragenyx Pharmaceutical, Inc. Target price 2024 - Analyst rating & recommendation

Ultragenyx Pharmaceutical, Inc. Classifications & Recommendation:

Buy
95%
Hold
5%

Ultragenyx Pharmaceutical, Inc. Price Target

Target Price $92.57
Price $44.75
Potential
Number of Estimates 21
21 Analysts have issued a price target Ultragenyx Pharmaceutical, Inc. 2025 . The average Ultragenyx Pharmaceutical, Inc. target price is $92.57. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 21 analysts: 20 Analysts recommend Ultragenyx Pharmaceutical, Inc. to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Ultragenyx Pharmaceutical, Inc. stock has an average upside potential 2025 of . Most analysts recommend the Ultragenyx Pharmaceutical, Inc. stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 434.25 541.99
19.52% 24.81%
EBITDA Margin -125.09% -92.01%
27.94% 26.44%
Net Margin -175.24% -106.61%
31.79% 39.16%

19 Analysts have issued a sales forecast Ultragenyx Pharmaceutical, Inc. 2024 . The average Ultragenyx Pharmaceutical, Inc. sales estimate is

$542m
Unlock
. This is
3.68% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$554m 5.92%
Unlock
, the lowest is
$534m 2.06%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $434m 19.52%
2024
$542m 24.81%
Unlock
2025
$635m 17.22%
Unlock
2026
$844m 32.89%
Unlock
2027
$1.2b 43.27%
Unlock
2028
$1.8b 49.37%
Unlock

6 Analysts have issued an Ultragenyx Pharmaceutical, Inc. EBITDA forecast 2024. The average Ultragenyx Pharmaceutical, Inc. EBITDA estimate is

$-499m
Unlock
. This is
0.47% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-403m 19.66%
Unlock
, the lowest is
$-542m 8.20%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-543m 13.88%
2024
$-499m 8.19%
Unlock
2025
$-446m 10.66%
Unlock
2026
$-237m 46.92%
Unlock
2027
$154m 165.10%
Unlock
2028
$247m 60.62%
Unlock

EBITDA Margin

2023 -125.09% 27.94%
2024
-92.01% 26.44%
Unlock
2025
-70.13% 23.78%
Unlock
2026
-28.01% 60.06%
Unlock
2027
12.73% 145.45%
Unlock
2028
13.69% 7.54%
Unlock

20 Ultragenyx Pharmaceutical, Inc. Analysts have issued a net profit forecast 2024. The average Ultragenyx Pharmaceutical, Inc. net profit estimate is

$-578m
Unlock
. This is
3.03% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-550m 7.74%
Unlock
, the lowest is
$-620m 4.02%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-761m 18.48%
2024
$-578m 24.07%
Unlock
2025
$-471m 18.49%
Unlock
2026
$-297m 36.96%
Unlock
2027
$-24.9m 91.61%
Unlock
2028
$369m 1,582.25%
Unlock

Net Margin

2023 -175.24% 31.79%
2024
-106.61% 39.16%
Unlock
2025
-74.14% 30.46%
Unlock
2026
-35.17% 52.56%
Unlock
2027
-2.06% 94.14%
Unlock
2028
20.43% 1,091.75%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -8.25 -6.26
18.48% 24.12%
P/E negative
EV/Sales 8.16

20 Analysts have issued a Ultragenyx Pharmaceutical, Inc. forecast for earnings per share. The average Ultragenyx Pharmaceutical, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-6.26
Unlock
. This is
3.10% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-5.96 7.74%
Unlock
, the lowest is
$-6.72 4.02%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-8.25 18.48%
2024
$-6.26 24.12%
Unlock
2025
$-5.11 18.37%
Unlock
2026
$-3.22 36.99%
Unlock
2027
$-0.27 91.61%
Unlock
2028
$4.00 1,581.48%
Unlock

P/E ratio

Current -6.93 78.15%
2024
-7.14 3.03%
Unlock
2025
-8.76 22.69%
Unlock
2026
-13.90 58.68%
Unlock
2027
-165.74 1,092.37%
Unlock
2028
11.18 106.75%
Unlock

Based on analysts' sales estimates for 2024, the Ultragenyx Pharmaceutical, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 8.46 2.92%
2024
8.16 3.51%
Unlock
2025
6.96 14.69%
Unlock
2026
5.24 24.75%
Unlock
2027
3.66 30.20%
Unlock
2028
2.45 33.05%
Unlock

P/S ratio

Current 7.91 13.19%
2024
7.62 3.55%
Unlock
2025
6.50 14.69%
Unlock
2026
4.89 24.75%
Unlock
2027
3.42 30.20%
Unlock
2028
2.29 33.05%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today